Bristol Myers is the latest drug company to sue HHS over payment terms for 340B hospitals

Taking stock of the drug industry, from the lab to the medicine chest

November 27, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Courtesy Bristol Myers Squibb STAT+ | Bristol Myers is the latest drug company to sue HHS over payment terms for 340B hospitals Bristol wants to issue rebates for its Eliquis blood thinner, but the Biden administration maintained such a switch would violate federal law. By Ed Silverman STAT+ | It might be now or never for the BIOSECURE Act The law is intended to crack down on Chinese biotech companies, but it may become more difficult to pass next year. By John Wilkerson STAT+ | Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger AI biotech companies like Recursion are expensive to build, and some of the early clinical readouts have underwhelmed investors. By Allison DeAngelis Drew Angerer/Getty Images Trump taps biotech investor Jim O'Neill for HHS deputy secretary O'Neill is close with billionaire Peter Thiel and worked on health care in the George W. Bush administration. By Lizzy Lawrence

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser